Search - tctmd.com

Displaying 961 - 980 of 1104

Sort: Relevancy | Date

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

Presentation TCT Russia 2012

DES Thrombosis: Emerging Concepts into Mechanisms and Prevention

Presenter: Gary S. Mintz

May 28, 2012

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Daily News

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

May 04, 2012

News Daily News

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

May 04, 2012

Presentation

New Oral Anticoagulants for Stroke Prevention

Presenter: Nicole R. Gonzales

May 02, 2012

News Daily News

Provisional Heparin Feasible for Preventing Occlusion in Transradial Catheterization

April 30, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Caitlin E. Cox

April 26, 2012

Presentation TCTAP 2012

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

Presentation TCTAP 2012

Transcatheter Aortic Valve Implantation - Stroke: Etiology and Prevention

Presenter: Corrado Tamburino

April 25, 2012

News Industry News

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

April 25, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation GI2 2012

New Agents and Prevention of Contrast Induced Nephropathy

Presenter: George Dangas

April 12, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

L.A. McKeown

March 26, 2012

News Conference News ACC 2012

Coronary CTA Effective, Efficient in Ruling Out Patients With Suspected ACS

Jason Kahn

March 26, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Advertisement

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

DES Thrombosis: Emerging Concepts into Mechanisms and Prevention

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

New Oral Anticoagulants Top Warfarin in A-fib Stroke Prevention

Los Nuevos Anticoagulantes Orales Superan a la Warfarina en la Prevención del ACV en pacientes con Fibrilación Auricular

New Oral Anticoagulants for Stroke Prevention

Provisional Heparin Feasible for Preventing Occlusion in Transradial Catheterization

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Transcatheter Aortic Valve Implantation - Stroke: Etiology and Prevention

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

New Agents and Prevention of Contrast Induced Nephropathy

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

Coronary CTA Effective, Efficient in Ruling Out Patients With Suspected ACS

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content